GAITHERSBURG, Md., Feb. 26, 2013 /PRNewswire/ -- Innovative Therapies Inc (ITI) announced today it has launched a new website (www.itimedical.com) and appointed a new executive management team for the negative pressure wound therapy division.
Richard Vogel, CEO, founded ITI in 2006 and has served as ITI’s full-time President and CEO since 2008. Richard has held CEO/President/COO and General Manager positions at several medical device, pharmaceutical, and biotech companies such as Kinetic Concepts, Inc. and American Cyanamid Company.
Dave Tumey, Chief Technology Officer (CTO), has 24 years experience in the field of biomedical R&D, including Director of V.A.C. R&D at Kinetic Concepts Inc. (KCI). Dave has fifty-four issued patents with many others pending, and has a background in electrical engineering.
Matt Dambeck, Chief Operating Officer (COO), recently joined Innovative Therapies from Stryker and is responsible for operations, sales and clinical service delivery. He has 10 years’ experience in the medical device industry, most recently as an Area Director of Sales.
Sandra Berriman, Ph.D., Vice President of Medical Affairs, has over 18 years experience in advancing pharmaceutical and medical device entities into the healthcare marketplace. While at Pfizer, her clinical team developed and launched Toviaz, as well as scientifically supported Detrol LA and Viagra.
Christine Grogan, Vice President of Marketing, has over 20 years of healthcare experience in medical and consumer marketing, sales, sales training and management at Allergan, Pfizer, and Parke Davis. She has held key leadership roles as Director of Botox and Senior Director of Breast Implants at Allergan. Christine stated that this new website would be invaluable to health care providers in the wound care space as well as for patients looking for more information about the benefits of negative pressure wound therapy.
Richard Vogel stated that “This newly appointed executive team has vast experience in launching blockbuster medical products, and is committed to ensuring that patients in the wound care space get the best therapy that this field can offer.”
SOURCE Innovative Therapies Inc
